Money-Back Guarantees for Expensive Drugs: Wolf's Clothing but a Sheep Underneath

In this issue, Kazi and colleagues show that a money-back guarantee for the lipid-lowering drug evolocumab will improve the drug's net cost-effectiveness by approximately 3% at most. The editorialists discuss why such guarantees for expensive drugs are more marketing legerdemain than an effective way to moderate drug costs.

https://ift.tt/2pYPiNp